The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Key takeaways in hemonc at ASCO 2022
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights key updates in hematological oncology (hem-onc) at the American Society of Clinical Oncology (ASCO) Annual Meeting, including novel JAK inhibitors such as pacritinib and momelotinib in patients with myeloproliferative neoplasms, as well as immunotherapy and CAR T-cell therapies being explored in lymphoma and multiple myeloma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
